In August 2024, PROFID and the PROFID EHRA trial were featured at the ESC 2024 Congress in London, marking a significant milestone in its ongoing efforts to reshape the future of cardiology. The event served as a platform to showcase the progress and impact of PROFID and the PROFID EHRA trial , demonstrating the project’s growing influence in addressing one of the most critical issues in cardiovascular health: preventing sudden cardiac death.

Several key activities at the congress highlighted the depth of PROFID’s work and its potential to change clinical practices:

• Steering Committe and National Coordinator Meeting, Investigator Meeting: These meetings brought together renowned researchers, steering committee members, and national coordinators. They provided an invaluable opportunity for thought leaders to engage in meaningful discussions, refine research strategies, and identify key challenges and opportunities in the fight against SCD.

• Joint Booth: A dedicated booth presented the main objectives and achievements of PROFID and the PROFID EHRA trial, reaching a diverse and engaged audience. The booth not only served as an information hub but also created a space for in-depth conversations about the project’s objectives, methodologies, and latest findings.

• ESC TV Connect Session: This recorded session with Dr. Valentina Kutyifa, Prof. Dr. Chris Gale, and Dr. Nikolaos Dagres provided a global platform to present the goals and impact of PROFID and the PROFID EHRA trial, as well as the scientific background. It engaged a wide international audience and offered valuable insights into the project’s ongoing contributions to the field. The session served as an excellent opportunity to communicate the project’s progress and demonstrate its role in shaping the future of cardiac care, particularly concerning the use of implantable cardioverter-defibrillators (ICDs). The recording is available here.

These activities were all part of a concerted effort to underscore PROFID and the PROFID EHRA trial increasing recognition as a leading initiative in the fight against sudden cardiac death. The primary focus of these presentations was to highlight the project’s ongoing work to redefine the role of prophylactic ICDs in preventing SCD in patients with a reduced left ventricular ejection fraction (LVEF) ≤ 35% after a myocardial infarction. Through these efforts, PROFID aims to improve patient outcomes and provide better, evidence-based solutions for clinicians treating high-risk heart patients.